trial

Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants

NCTId NCT01879722
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 77 (actual)
Sponsored by Takeda
Primary completion 2014-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
77 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2013-06
Primary completion
2014-06
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
TAK-063

Sponsors

TakedaLead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
77
Phase
PHASE1
Primary Completion Date
2014-06
Status
COMPLETED
relationships
The graph out of here
drug
TAK-063
drug
lead_sponsor
Takeda
company
indication
Schizophrenia
indication
Schizophrenia
indication